FDA advisory highlights supplement excipient
This article was originally published in The Tan Sheet
Executive SummaryOne lot of crospovidone from Chinese firm Tianjin Boai NKY International contains peroxide levels more than four times higher than the maximum set by global standards, FDA says Oct. 21. Although not a significant health risk, the peroxide could cause a loss of potency in dietary supplements and pharmaceuticals that use crospovidone and other providone analogues, the agency says. Daniel Fabricant, VP of scientific and regulatory affairs for the Natural Products Association, said the excipient aids dissolution in tablets and softgels, and the high peroxide levels likely signal ingredients past their shelf life expiry. FDA's advisory reminds supplement makers "it's another spec they need to be looking for" in their excipients, Fabricant said
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.